Ocugen (NASDAQ:OCGN) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Ocugen (NASDAQ:OCGN) in a research report report published on Monday morning,Benzinga reports. They currently have a $7.00 price objective on the stock.

Other equities analysts have also recently issued reports about the stock. Chardan Capital reaffirmed a “buy” rating and set a $6.00 price target on shares of Ocugen in a research note on Friday. Maxim Group began coverage on shares of Ocugen in a report on Tuesday, October 15th. They issued a “buy” rating and a $4.00 target price for the company.

Ocugen Price Performance

Shares of OCGN opened at $1.06 on Monday. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.09. The stock’s 50 day moving average is $1.03 and its two-hundred day moving average is $1.35. Ocugen has a twelve month low of $0.35 and a twelve month high of $2.11. The firm has a market capitalization of $305.13 million, a PE ratio of -5.63 and a beta of 3.75.

Institutional Investors Weigh In On Ocugen

A number of institutional investors and hedge funds have recently bought and sold shares of OCGN. Xponance Inc. purchased a new stake in shares of Ocugen in the second quarter valued at $25,000. Baader Bank Aktiengesellschaft acquired a new stake in Ocugen during the second quarter worth approximately $35,000. Victory Capital Management Inc. acquired a new position in Ocugen in the 2nd quarter valued at $51,000. Headlands Technologies LLC acquired a new stake in shares of Ocugen during the first quarter worth $66,000. Finally, Daiwa Securities Group Inc. purchased a new position in Ocugen during the second quarter worth about $67,000. Hedge funds and other institutional investors own 10.27% of the company’s stock.

About Ocugen

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.